相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge
Jiyue Zheng et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Coffee consumption and all-cause and cause-specific mortality: a meta-analysis by potential modifiers
Youngyo Kim et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2019)
Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: A single-arm, open-label, prospective, multicenter study
Mutsumi Iijima et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
The physiological effects of caffeine on synaptic transmission and plasticity in the mouse hippocampus selectively depend on adenosine A1 and A2A receptors
Joao P. Lopes et al.
BIOCHEMICAL PHARMACOLOGY (2019)
A new therapeutic strategy with istradefylline for postural deformities in Parkinson's disease
Shinsuke Fujioka et al.
NEUROLOGIA I NEUROCHIRURGIA POLSKA (2019)
Effect of istradefylline on mood disorders in Parkinson's disease
Hiroshi Nagayama et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2019)
Impact of genetic variations in ADORA2A gene on depression and symptoms: a cross-sectional population-based study
Silvia Oliveira et al.
PURINERGIC SIGNALLING (2019)
The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson's disease
Keita Matsuura et al.
NEUROSCIENCE LETTERS (2018)
Association of coffee consumption and non-motor symptoms in drug-naive, early-stage Parkinson's disease
Bang-Hoon Cho et al.
PARKINSONISM & RELATED DISORDERS (2018)
Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?
Margherita Torti et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Delphine Charvin et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan
Makio Takahashi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Neuronal Adenosine A2A Receptors Are Critical Mediators of Neurodegeneration Triggered by Convulsions
Paula M. Canas et al.
ENEURO (2018)
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
Fabrizio Stocchi et al.
NEUROLOGY (2017)
The effect of istradefylline for Parkinson's disease: A meta-analysis
Wataru Sako et al.
SCIENTIFIC REPORTS (2017)
Optogenetic Activation of Adenosine A2A Receptor Signaling in the Dorsomedial Striatopallidal Neurons Suppresses Goal-Directed Behavior
Yan Li et al.
NEUROPSYCHOPHARMACOLOGY (2016)
How does adenosine control neuronal dysfunction and neurodegeneration?
Rodrigo A. Cunha
JOURNAL OF NEUROCHEMISTRY (2016)
The epidemiology of Parkinson's disease: risk factors and prevention
Alberto Ascherio et al.
LANCET NEUROLOGY (2016)
An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models
Wai Kin D. Ko et al.
NEUROPHARMACOLOGY (2016)
A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
Tomoyoshi Kondo et al.
CLINICAL NEUROPHARMACOLOGY (2015)
Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models
Wei Li et al.
NEUROBIOLOGY OF DISEASE (2015)
Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress
Manuella P. Kaster et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease Two Randomized Clinical Trials and Lessons Learned
Robert A. Hauser et al.
JAMA NEUROLOGY (2015)
Regulation of Fear Responses by Striatal and Extrastriatal Adenosine A2A Receptors in Forebrain
Catherine J. Wei et al.
BIOLOGICAL PSYCHIATRY (2014)
Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
Annalisa Pinna
CNS DRUGS (2014)
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2014)
Overexpression of adenosine A2A receptors in rats: effects on depression, locomotion, and anxiety
Joana E. Coelho et al.
FRONTIERS IN PSYCHIATRY (2014)
Caffeine and Adenosine A2A Receptor Inactivation Decrease Striatal Neuropathology in a Lentiviral-Based Model of Machado-Joseph Disease
Nelio Goncalves et al.
ANNALS OF NEUROLOGY (2013)
Istradefylline: First Global Approval
Rosselle Dungo et al.
DRUGS (2013)
Adenosine A2A receptor deficiency alleviates blast-induced cognitive dysfunction
Ya-Lei Ning et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2013)
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
Stewart A. Factor et al.
MOVEMENT DISORDERS (2013)
Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2013)
Adenosine receptors as drug targets - what are the challenges?
Jiang-Fan Chen et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects
D. L. Cutler et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2012)
Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM
N. Amin et al.
MOLECULAR PSYCHIATRY (2012)
No Thanks, Coffee Keeps Me Awake: Individual Caffeine Sensitivity Depends on ADORA2A Genotype
Hans-Peter Landolt
SLEEP (2012)
Recent developments in adenosine receptor ligands and their potential as novel drugs
Christa E. Mueller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2011)
Deletion of adenosine A1 or A2A receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease
Danqing Xiao et al.
BRAIN RESEARCH (2011)
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease
R. A. Popat et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Preclinical jockeying on the translational track of adenosine A2A receptors
Melita T. Barkhoudarian et al.
EXPERIMENTAL NEUROLOGY (2011)
Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: Rationale and design of a prospective, randomized, multicenter study
Furqan H. Tejani et al.
JOURNAL OF NUCLEAR CARDIOLOGY (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee
Taye H. Hamza et al.
PLOS GENETICS (2011)
Recent Caffeine Ingestion Reduces Adenosine Efficacy in the Treatment of Paroxysmal Supraventricular Tachycardia
Miguel S. Cabalag et al.
ACADEMIC EMERGENCY MEDICINE (2010)
An Open-Label, Positron Emission Tomography Study to Assess Adenosine A(2A) Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers
David J. Brooks et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Adenosine A2A receptor gene: Evidence for association of risk variants with panic disorder and anxious personality
Christa Hohoff et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2010)
Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2010)
Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
H. H. Fernandez et al.
PARKINSONISM & RELATED DISORDERS (2010)
Genetics of caffeine consumption and responses to caffeine
Amy Yang et al.
PSYCHOPHARMACOLOGY (2010)
Preferential enhancement of working memory in mice lacking adenosine A2A receptors
Sai-jun Zhou et al.
BRAIN RESEARCH (2009)
Adenosine A(2A) Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition
Hai-Ying Shen et al.
CURRENT NEUROPHARMACOLOGY (2009)
Genetic inactivation of adenosine A(2A) receptors attenuates acute traumatic brain injury in the mouse cortical impact model
Wei Li et al.
EXPERIMENTAL NEUROLOGY (2009)
Adenosine A2A Receptor Blockade Prevents Synaptotoxicity and Memory Dysfunction Caused by β-Amyloid Peptides via p38 Mitogen-Activated Protein Kinase Pathway
Paula M. Canas et al.
JOURNAL OF NEUROSCIENCE (2009)
Adenosine, adenosine A2A antagonists, and Parkinson's disease
P. Jenner et al.
PARKINSONISM & RELATED DISORDERS (2009)
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces Off' time in Parkinson's disease:: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter A. LeWitt et al.
ANNALS OF NEUROLOGY (2008)
Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders
Rodrigo A. Cunha et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway
Susana Mingote et al.
JOURNAL OF NEUROSCIENCE (2008)
Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctuations
Robert A. Hauser et al.
MOVEMENT DISORDERS (2008)
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk
Karen M. Powers et al.
MOVEMENT DISORDERS (2008)
FGF acts as a co-transmitter through adenosine A2A receptor to regulate synaptic plasticity
Marc Flajolet et al.
NATURE NEUROSCIENCE (2008)
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
M. Stacy et al.
NEUROLOGY (2008)
Prospective study of coffee consumption and risk of Parkinson's disease
K. Saaksjarvi et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2008)
Adenosine A2A receptors and basal ganglia physiology
S. N. Schiffmann et al.
PROGRESS IN NEUROBIOLOGY (2007)
The premotor phase of Parkinson's disease
E. Tolosa et al.
PARKINSONISM & RELATED DISORDERS (2007)
Th effect of striatal dopamine depletion and the adenosine A2A antagonist KW-6002 on reversal learning in rats
Martin O'Neill et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2007)
D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons
D. James Surmeier et al.
TRENDS IN NEUROSCIENCES (2007)
Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice
Oscar P. Dall'Igna et al.
EXPERIMENTAL NEUROLOGY (2007)
Targeting adenosine A2A receptors in Parkinson's disease
Michael A. Schwarzschild et al.
TRENDS IN NEUROSCIENCES (2006)
Non-motor symptoms of Parkinson's disease: diagnosis and management
KR Chaudhuri et al.
LANCET NEUROLOGY (2006)
Psychiatric aspects of Parkinson's disease - An Update
A Schrag
JOURNAL OF NEUROLOGY (2004)
Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A(2A) receptors
MV Sitkovsky et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Adenosine A2A-dopamine D2 receptor-receptor heteromerization -: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer
M Canals et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Prospective study of caffeine consumption and risk of Parkinson's disease in men and women
A Ascherio et al.
ANNALS OF NEUROLOGY (2001)
Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease
JF Chen et al.
JOURNAL OF NEUROSCIENCE (2001)
Inactivation of adenosine A(2A) receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission
P D'Alcantara et al.
NEUROSCIENCE (2001)
Association of coffee and caffeine intake with the risk of Parkinson disease
GW Ross et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
